HOME >> MEDICINE >> NEWS
ENBREL (Etanercept) Patient And Physician Support Web Site Launched

Web Site Offers Important Information And Support Programs For People With Rheumatoid Arthritis And For Their Health Care Providers

SEATTLE, April 6, 1999 - In an effort to better educate patients and health care providers about ENBREL (etanercept), a breakthrough treatment for rheumatoid arthritis (RA), Immunex Corporation and Wyeth-Ayerst Pharmaceuticals have launched the ENBREL Web Site: www.enbrel.com. ENBREL is used to treat moderately to severely active rheumatoid arthritis in people who have not adequately responded to one or more disease-modifying anti-rheumatic drugs (DMARDs).

The comprehensive internet site explains how ENBREL works in the body, offers a question and answer section, provides an interactive quiz to help RA sufferers and their doctors determine if ENBREL may be right for them, and highlights several patients' personal experiences with ENBREL. Color photography and animation add to the graphic interest of the site.

Enbrel.com also offers two toll-free numbers to provide support to patients who are considering or are currently taking ENBREL. For questions about insurance coverage, patients can call the Reimbursement Support Line (1-800-282-7704) where they will be connected with an insurance specialist. To answer any noninsurance questions about ENBREL and RA in general, trained telephone counselors are available at 1-888-4ENBREL. A link to the Arthritis Foundation Web Site is also provided.

Approximately 2.1 million Americans suffer from rheumatoid arthritis, an autoimmune disease that can strike at any age and affects three times as many women as men. ENBREL is the first in a class of rheumatoid arthritis drugs known as biologic response modifiers (BRMs), a new approach to RA management and the first breakthrough treatment in many years for people with rheumatoid arthritis.

In medical studies, just over one third of people treated with ENBREL (etanercept) rep
'"/>

Contact: Tim Warner
warnert@immunex.com
206-470-4193
Immunex Corporation
6-Apr-1999


Page: 1 2

Related medicine news :

1. ENBREL (etanercept) long-term clinical trial data
2. ENBREL application for early, active rheumatoid arthritis filed with the U.S. Food and Drug Administration
3. Circulation publishes phase I study of ENBREL in patients with chronic heart failure
4. ENBREL (Etanercept) Receives FDA Approval For Treatment Of Juvenile Rheumatoid Arthritis
5. Positive Results Of Pivotal Phase III Trial With ENBREL In Patients With Early, Active Rheumatoid Arthritis
6. ENBREL Phase III Data Published In Annals Of Internal Medicine
7. Patients newly diagnosed with HIV are more likely to enter outpatient care with case management
8. Patient with drug-resistant form of HIV identified
9. Patient knows best when it comes to ulcerative colitis, U-M study finds
10. Patients with cancer have highly increased risk for blood clots
11. Patients with previous heart attacks may not benefit from pacemaker implant

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: ENBREL Etanercept Patient And Physician Support Web Site Launched

(Date:11/24/2014)... (PRWEB) November 24, 2014 Global ... 6.19 billion by 2020, according to a new ... rates of cardiac arrhythmias clubbed with growing global ... this market. Though still in the budding stage, ... rise in usage rates in the recent times, ...
(Date:11/24/2014)... 2014 Residents of retirement communities in ... year’s SENIORS GOT TALENT, an annual online talent competition ... players to classic crooners, to seniors partying on a ... are indeed living young. , “SENIORS GOT TALENT, while ... cash prize, has always been about highlighting the vibrancy ...
(Date:11/24/2014)... York (PRWEB) November 24, 2014 The ... by the Family and Children's Association to ... as soap, shampoo, mouthwash and other such items.The Association's ... who are home bound, living in nursing homes, assisted ... to greatly enhance the well being of seniors throughout ...
(Date:11/24/2014)... SafeHandles™ announced that they will be featured ... Jr, airing via Discovery Channel. Dates and show times ... non-invasive, replaceable, and affordable germ protective device. This segment ... and adhesives to promote hand hygiene in high traffic ... SafeHandles is the desire to make a positive impact ...
(Date:11/24/2014)... Pittsburgh, PA (PRWEB) November 24, 2014 ... as he was trying to cross the street in ... "The driver never saw him. I came up with ... easily visible at night." , He developed the Safety ... night or in low-lighting conditions. The device ensures that ...
Breaking Medicine News(10 mins):Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 2Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 3Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 4Health News:Nursing Homes & Assisted Living Retirement Communities Enter Seniors Guide's Seniors Got Talent 2Health News:Nursing Homes & Assisted Living Retirement Communities Enter Seniors Guide's Seniors Got Talent 3Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 2Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 3Health News:New Episode of Innovations TV Series to Feature SafeHandles™ 2
(Date:11/24/2014)... 2014  GlySens Incorporated announced today that it has ... the National Institute of Diabetes and Digestive and Kidney ... Health (NIH).  The grant is intended to support human ... term implantable glucose monitoring system.  Final preparations for launch ... to begin before the end of 2014. ...
(Date:11/23/2014)... Nov. 23, 2014 Anthera Pharmaceuticals, Inc. (Nasdaq: ... F. Truex , President and Chief Executive Officer, will ... Jaffray Healthcare Conference. Anthera will present ... Palace Hotel in New York City ... Anthera Pharmaceuticals is a biopharmaceutical company focused on developing ...
(Date:11/22/2014)... NEWTOWN, Pennsylvania , 21 de noviembre de ... servicios de ensayos clínicos externalizados y tecnologías eClinical, ... su aproximación de ,seguimiento inteligente, para el seguimiento ... El seguimiento inteligente amplía el concepto del seguimiento ... simple reducción de las visitas de seguimiento o ...
Breaking Medicine Technology:GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health 2Anthera Pharmaceuticals to Present at Annual Piper Jaffray Healthcare Conference 2El 'seguimiento inteligente' consigue un excelente momento 2El 'seguimiento inteligente' consigue un excelente momento 3
Cached News: